Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Jeil Pharmaceutical Co. Ltd. (271980) Stock Price & Analysis

271980 Stock Chart & Stats

₩8,700.00-₩20.00(-0.23%)
At close: 3:30 PM GMT+9
₩9K₩10K₩11KAug 10Aug 24Sep 7Sep 21Oct 6Oct 19Nov 2
Day’s Range
KRW 8,480.00 - KRW 8,750.00
52-Week Range
KRW 8,480.00 - KRW 19,290.00
Previous Close
KRW 8,720.00
Volume
N/A
Average Volume (3M)
15.56K
Market Cap
KRW 127.06B
Enterprise Value
KRW 242.45B
Total Cash (Recent Filing)
KRW 67.41B
Total Debt (Recent Filing)
KRW 112.28B
Price to Earnings (P/E)
7.2
Beta
0.19
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Dec 27, 2023
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Profitability Recovery

The return to positive TTM net income marks a meaningful recovery from the loss-making period in 2021–2024. Combined with a gross margin near 39%, this indicates the core product portfolio retains economic value and provides a foundation for rebuilding earnings over the coming quarters.

Moderate Leverage

Moderate leverage and relatively stable equity give Jeil Pharmaceutical a more manageable financial base than a highly indebted business. Asset growth also suggests the company retains capacity to support operations and investment, although future returns will depend on restoring stronger profitability.

Integrated Pharmaceutical Model

Jeil Pharmaceutical spans development, manufacturing, and commercialization rather than operating in only one activity. This integrated prescription-medicine model can support continuity from product creation through market supply and gives the company multiple operating capabilities within healthcare.

Bears Say

Weak Cash Conversion

Negative free cash flow means recent operations have not fully funded spending and working-capital needs. The repeated history of negative operating cash flow also points to inconsistent cash conversion, which can constrain reinvestment and increase liquidity pressure during weaker operating periods.

Operating Margin Compression

The decline in EBIT margin shows that improved net profitability has not translated into sustained operating-strength expansion. If margins remain near the lower TTM level, reduced operating earnings will limit internal funding, weaken resilience, and make future profit growth more dependent on revenue recovery.

Volatile Revenue Trend

An uneven revenue trajectory reduces visibility into the company’s underlying demand and makes earnings planning less dependable. The reported negative growth rate, together with the noted volatility, indicates that margin recovery may not be durable unless Jeil can establish more consistent sales expansion.

271980 FAQ

What was Jeil Pharmaceutical Co. Ltd.’s price range in the past 12 months?
Jeil Pharmaceutical Co. Ltd. lowest stock price was ₩8480.00 and its highest was ₩19290.00 in the past 12 months.
What is Jeil Pharmaceutical Co. Ltd.’s market cap?
Jeil Pharmaceutical Co. Ltd.’s market cap is ₩127.06B.
When is Jeil Pharmaceutical Co. Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Jeil Pharmaceutical Co. Ltd.’s earnings last quarter?
Jeil Pharmaceutical Co. Ltd. released its earnings results on Aug 14, 2026. The company reported -₩545.232 earnings per share for the quarter.
Is Jeil Pharmaceutical Co. Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Jeil Pharmaceutical Co. Ltd. pay dividends?
Jeil Pharmaceutical Co. Ltd. pays a ― dividend of ₩50 which represents an annual dividend yield of ―. See more information on Jeil Pharmaceutical Co. Ltd. dividends here
What is Jeil Pharmaceutical Co. Ltd.’s EPS estimate?
Jeil Pharmaceutical Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jeil Pharmaceutical Co. Ltd. have?
Jeil Pharmaceutical Co. Ltd. has 14,704,872 shares outstanding.
What happened to Jeil Pharmaceutical Co. Ltd.’s price movement after its last earnings report?
Jeil Pharmaceutical Co. Ltd. reported an EPS of -₩545.232 in its last earnings report. Following the earnings report the stock price went down -1.564%.
Which hedge fund is a major shareholder of Jeil Pharmaceutical Co. Ltd.?
Currently, no hedge funds are holding shares in KR:271980
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology